Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A securities class action has been filed against Aardvark Therapeutics and certain officers on behalf of investors who bought shares in its February 13, 2025 IPO or between February 13, 2025 and May 14, 2026. The complaint alleges that the company overstated the safety and clinical, regulatory and commercial prospects of ARD-101, while making materially misleading statements or omissions. Investors seeking lead-plaintiff status must apply by October 13, 2026; the litigation creates potential financial and reputational risks for Aardvark.

Analysis

This is principally a financing-risk signal rather than a litigation-liability event. For a clinical-stage issuer, the relevant transmission mechanism is whether the alleged safety issues alter the probability-adjusted value of ARD-101 and force a capital raise before a credible clinical or regulatory de-risking event. The lawsuit itself is not independently probative: plaintiff-firm announcements commonly follow equity declines and rarely create material cash exposure relative to biotech operating risk.

Near term, expect a modest liquidity discount through the October 13 lead-plaintiff deadline, particularly if borrow is available and daily turnover is thin; that can widen bid/ask spreads and make any subsequent dilutive financing more punitive. Over the next 1-3 months, the critical catalyst is management’s quantified safety disclosure—adverse-event rate, seriousness, discontinuations, dose relationship, and FDA interactions—not procedural milestones in the suit. A safety signal that requires protocol changes, enrollment pause, dose reduction, or revised trial endpoints would impair both timeline and peak-sales assumptions, likely producing a larger valuation reset than the legal headline.

Consensus may over-attribute causality to the lawsuit. If the underlying disclosed events are already reflected in trial materials and no regulator action or guidance revision follows, forced selling around litigation headlines can reverse quickly; there is no clean sector read-through to obesity/rare-disease biotech peers without evidence that the issue is target-, dose-, or indication-specific. The structural downside remains asymmetric if cash runway is short, because a lower share price raises dilution per dollar of required capital.

Key Decisions for Investors

• Do not initiate a fundamental short solely on the filing; treat AARD as an avoid/watch until the complaint and underlying clinical disclosures establish whether there is new, non-publicly incorporated safety information.
• Set an event alert for any FDA hold, protocol amendment, enrollment interruption, or safety-guidance revision over the next 1-3 months. Any of these would validate a bearish position; absence of such action after the next formal clinical update would weaken the thesis.
• Before taking exposure, quantify AARD cash runway versus quarterly operating burn and the next meaningful data/regulatory milestone. If runway ends before that milestone, a short or put structure after an initial litigation-driven bounce offers better asymmetry; invalidate on a non-dilutive partnership, financing at a premium, or clean updated safety data.
• For existing long holders, reduce position size rather than hedge with near-dated options unless implied volatility is demonstrably below expected event volatility; thin-liquidity biotech options can embed excessive premium. Reassess after management provides adverse-event and discontinuation detail.